Clinical Trials for Small Cell Lung Cancer

A Phase 1/2 Trial of Ivonescimab With Dato-DXd or Osimertinib in Patients With Metastatic EGFR-mutant Non-small Cell Lung Cancer That Progressed on EGFR TKI Therapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic activating EGFR-mutant NSCLC progressing after prior third-generation EGFR TKI and platinum chemotherapy, or platinum-ineligible, receive ivonescimab, a bispecific PD-1/VEGF antibody, combined with either datopotamab deruxtecan, a TROP2-directed topoisomerase I ADC, or osimertinib. The study includes patients with ECOG 0–1 and measurable disease, allowing controlled/asymptomatic CNS disease.

ClinicalTrials.gov ID: NCT07535437

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 small cell lung cancer, including previously treated recurrent/progressive SCLC and a cohort of treatment-naive extensive-stage SCLC after ≤1 cycle of platinum chemotherapy. Patients receive IV tarlatamab, a DLL3×CD3 bispecific T-cell engager, plus ZL-1310/zocilurtatug pelitecan, an investigational DLL3-targeted topoisomerase I ADC, with durvalumab anti–PD-L1 added in the first-line ES-SCLC triplet cohort.

ClinicalTrials.gov ID: NCT07531095

A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated extensive-stage SCLC and ECOG 0–1 receive first-line YL201, an investigational B7-H3–directed antibody–drug conjugate with a topoisomerase I inhibitor payload, plus atezolizumab. The study is testing escalating/optimized YL201 doses with fixed-dose PD-L1 blockade, without platinum-etoposide chemotherapy.

ClinicalTrials.gov ID: NCT07407933

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with measurable first-line ES-SCLC, either treatment-naïve or without progression after 3–4 cycles of platinum/etoposide plus anti–PD-1/PD-L1 therapy. Regimens test gocatamig/MK-6070, a DLL3/CD3 trispecific T-cell engager, plus ifinatamab deruxtecan/MK-2400, a B7-H3–directed topoisomerase I ADC, as maintenance and/or induction-maintenance therapy, with a standard carboplatin/etoposide/atezolizumab comparator in untreated patients.

ClinicalTrials.gov ID: NCT07227597

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults aged 18–75 with measurable locally advanced or metastatic protocol-specified epithelial solid tumors, ECOG 0–1, and applicable molecular testing are eligible. Treatment is IV AVZO-1418, an EGFR/HER3-targeted bispecific antibody–drug conjugate delivering a topoisomerase I inhibitor payload, as monotherapy with potential protocol-defined combination cohorts.

ClinicalTrials.gov ID: NCT07038343

A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors harboring specified RAS mutations, ECOG 0–1, generally without acceptable standard systemic options; a newly diagnosed pancreatic ductal adenocarcinoma cohort is also eligible. Patients receive oral ERAS-0015, a pan-RAS molecular glue that disrupts active RAS–effector interactions and inhibits MAPK signaling, alone or with other investigational anticancer agents.

ClinicalTrials.gov ID: NCT06983743

A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable ES-SCLC and ECOG 0–1 after progression on platinum-doublet chemotherapy plus a PD-L1 inhibitor receive lymphodepletion followed by DJI136, an autologous DLL3-directed CAR-T therapy armored with a dominant-negative TGF-β receptor II. Prior DLL3-targeted therapy is allowed in dose escalation but excluded from the phase II cohort.

ClinicalTrials.gov ID: NCT07564401

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial targets adult patients with non-small cell and small cell lung cancers experiencing oligo-progression while on stable systemic therapy, assessing the addition of locally ablative therapies like stereotactic ablative radiotherapy (SABR) and interventional radiology ablation for up to five or fewer metastatic lesions.

ClinicalTrials.gov ID: NCT06103682

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial investigates the safety and efficacy of [68Ga]Ga DOTA-5G for imaging and [177Lu]Lu DOTA-ABM-5G for treatment, targeting the integrin αvβ6, in up to 40 patients with metastatic non-small cell lung cancer who have progressed after previous treatments.

ClinicalTrials.gov ID: NCT06228482

Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adult patients with advanced solid tumors, including NSCLC, who have progressed after anti-PD-1/PD-L1 therapy to evaluate MEM-288, an oncolytic adenovirus with immunostimulatory properties, alone and in combination with the PD-1 inhibitor nivolumab.

ClinicalTrials.gov ID: NCT05076760